Selective suppression of polyglutamine-expanded protein by lipid nanoparticle-delivered siRNA targeting CAG expansions in the mouse CNS

Tomoki Hirunagi,1 Kentaro Sahashi,1 Kiyoshi Tachikawa,2 Angel I. Leu,2 Michelle Nguyen,2 Rajesh Mukthavaram,2 Priya P. Karmali,2 Padmanabh Chivukula,2 Genki Tohnai,1 Madoka Iida,1 Kazunari Onodera,1,3 Manabu Ohyama,4 Yohei Okada,3 Hideyuki Okano,3 and Masahisa Katsuno1

Polyglutamine (polyQ) diseases are inherited neurodegenerative disorders caused by expansion of cytosine-adenine-guanine (CAG)-trinucleotide repeats in causative genes. These diseases include spinal and bulbar muscular atrophy (SBMA), Huntington’s disease, dentatorubral-pallidolysian atrophy, and spinocerebellar ataxias. Targeting expanded CAG repeats is a common therapeutic approach to polyQ diseases, but concomitant silencing of genes with normal CAG repeats may lead to toxicity. Previous studies have shown that CAG repeat-targeting small interfering RNA duplexes (CAG-siRNAs) have the potential to selectively suppress mutant proteins in in vitro cell models of polyQ diseases. However, in vivo application of these siRNAs has not yet been investigated. In this study, we demonstrate that an unlocked nucleic acid (UNA)-modified CAG-siRNA shows high selectivity for polyQ-expanded androgen receptor (AR) inhibition in in vitro cell models and that lipid nanoparticle (LNP)-mediated delivery of the CAG-siRNA selectively suppresses mutant AR in the central nervous system of an SBMA mouse model. In addition, a subcutaneous injection of the LNP-delivered CAG-siRNA efficiently suppresses mutant AR in the skeletal muscle of the SBMA mouse model. These results support the therapeutic potential of LNP-delivered UNA-modified CAG-siRNAs for selective suppression of mutant proteins in SBMA and other polyQ diseases.

INTRODUCTION

Spinal and bulbar muscular atrophy (SBMA) is an X-linked and adult-onset neurodegenerative disorder caused by the expansion of trinucleotide cytosine-adenine-guanine (CAG) repeats, which encode a polyglutamine (polyQ) tract in the androgen receptor (AR) gene.1,2 SBMA belongs to the family of polyQ diseases, which also include Huntington’s disease (HD), dentatorubral-pallidolysian atrophy (DRPLA), and spinocerebellar ataxia (SCA) types 1, 2, 3, 6, 7, and 17.3–4 The characteristics of polyQ diseases include intracellular aggregates of polyQ-expanded proteins and degeneration of specific neuron populations. For instance, the brainstem and spinal motor neurons in SBMA, striatum and cerebral cortex in HD, and cerebellum in SCA are distinctively affected in the central nervous system (CNS) of patients. Those with polyQ diseases develop progressive neurological symptoms caused by the degeneration of neurons, and currently there is no curative therapy.

Reducing expanded polyQ proteins is a promising therapeutic strategy in polyQ diseases because toxic polyQ proteins play a central role in disease pathogenesis.3–4 The use of antisense oligonucleotides (ASOs) and RNA interference for silencing disease-causing genes has been intensively studied, and clinical trials applying chemically modified ASOs for HD have been launched based on the success of preclinical studies.5–7 Targeting CAG repeats is another potential therapeutic option in polyQ diseases.8 Peptide nucleic acid and locked nucleic acid oligomers complementary to CAG repeats were the first reported oligonucleotides with therapeutic potentials; they showed selective inhibition of expression of the mutant allele of huntingtin (HTT) and ataxin 3 (ATXN3).9 Further studies showed similar effects produced by ASOs with other types of chemical modification10 and small interfering RNA (siRNA) duplexes targeting expanded CAG repeats in HD, SCA3, and DRPLA cell lines.11–15 Moreover, recent studies have shown that chemically modified ASOs and single-stranded siRNAs targeting CAG repeats suppress mutant proteins in the CNS of HD,16,17 SCA1, and SCA318 mouse models. However,
the knockdown potency and selectivity of CAG repeat-targeting oligonucleotides against mutant AR has yet to be investigated in SBMA. Given that wild-type proteins with normal glutamine stretches have various functions in the CNS, selective suppression of mutant proteins with abnormal polyQ expansions is preferable, especially for early therapeutic intervention at presymptomatic stages. In cellular experiments, siRNAs that are fully complementary to CAG repeats showed limited allele selectivity, while those containing central mismatches showed high selectivity for a mutant allele of HTT. ASOs targeting CAG repeats also showed allele selectivity in HD knockin mouse models. However, the CAG repeats of endogenous mouse Htt gene are rather short; thus, it is unclear whether these oligomers can provide allele selectively in HD patients. Another study showed that striatum-injected locked nucleic acid-modified ASOs targeting CAG repeats did not reduce mutant HTT levels in an HD mouse model, although the ASOs ameliorated the phenotype independent of HTT levels. Overall, selective silencing of mutant proteins by CAG repeat-targeting oligonucleotides is yet to be investigated in vivo.

The aim of this study was to explore the potential application of CAG-siRNAs for mutant-allele-selective treatment for polyQ diseases in the context of cellular and mouse models of SBMA. After screening the optimal unlocked nucleic acid (UNA) position using a luciferase-ATXN3 reporter assay, we investigated whether CAG-siRNAs containing a central mismatch and UNA substitutions selectively suppress mutant AR protein in in vitro cell models. In addition, we in vivo administered a UNA-modified CAG-siRNA into the murine CNS and skeletal muscle using a lipid-enabled and UNA modified RNA (LUNAR) lipid delivery technology platform.

RESULTS

Screening the optimal UNA position in CAG-siRNAs with a luciferase-ATXN3 reporter assay

Before testing CAG-siRNAs in cell models of SBMA, we performed a luciferase reporter assay to determine the optimal position of UNA substitutions. We generated luciferase reporter vectors containing human ATXN3 with 24 or 74 expanded CAG repeats (Figure S1A) and screened them to identify siRNA candidates (Figure S1B) by co-transfection of the vectors and each 21-mer CAG-siRNA in HEK293 cells. First, we tested a CAG-siRNA that was fully complementary to the CAG repeats, namely "REP," and CAG-siRNAs with a central mismatch and different position of a UNA substitution. 5' UNA modifications of the sense strands were used to improve siRNA targeting in all tested siRNAs (Figure S1B). In accordance with previous results, the CAG-siRNA with a UNA modification at position 9 from the 5' end of the antisense strand (REPU9) showed high allele selectivity (nanomolar inhibitory concentration 50% (IC50) values against wild-type/nanomolar IC50 values against mutant [IC50 WT/IC50 MUT]: 7.84), with a 50% reduction in wild-type ATXN3 expression and 90% reduction in mutant ATXN3 expression at a concentration of 50 nM (Figures S1C and S1D). To further compare the potencies of CAG-siRNAs, we performed a second round of screening using CAG-siRNAs with different UNA modifications, including REP, REP9, U10, U910, and U1011. Of these, REP9 showed the highest selectivity (IC50 WT/IC50 MUT: 46.1), with a 30% reduction in wild-type ATXN3 and 90% reduction in mutant ATXN3 at a concentration of 50 nM (Figures S1E and S1F).

Selective suppression of mutant androgen receptor by UNA-modified siRNA targeting CAG repeats

Figure 1. Selective suppression of polyQ-expanded androgen receptor by UNA-modified siRNA targeting CAG repeats

(A) The nucleotide sequences and chemical modifications of the siRNA. Locked nucleic acid (LNA) substitutions are marked in bold. Underlining represents central mismatches. NTC, negative control. (B) western blot analysis of androgen receptor (AR) levels in healthy control (Q30) and SBMA (Q52) fibroblasts 48 h after transfection with the indicated siRNAs (25 nM). (C) Densitometric quantitation of AR band intensities shown in (B) (n = 3; N.S., not significant; *p < 0.05, **p < 0.01). (D) Knockdown effect of REP9 siRNA (0, 2.5, 5, and 25 nM) on AR protein levels in healthy control (Q30 and Q17) and SBMA (Q52 and Q48) fibroblasts. (E) Densitometric quantitation of AR band intensities shown in (D) (n = 3 for each concentration; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 One-way ANOVA with post hoc Dunnett’s test). Error bars mean standard deviation.

Given that wild-type proteins with normal glutamine stretches have various functions in the CNS, selective suppression of mutant proteins with abnormal polyQ expansions is preferable, especially for early therapeutic intervention at presymptomatic stages. In cellular experiments, siRNAs that are fully complementary to CAG repeats showed limited allele selectivity, while those containing central mismatches showed high selectivity for a mutant allele of HTT. ASOs targeting CAG repeats also showed allele selectivity in HD knockin mouse models. However, the CAG repeats of endogenous mouse Htt gene are rather short; thus, it is unclear whether these oligomers can provide allele selectively in HD patients. Another study showed that striatum-injected locked nucleic acid-modified ASOs targeting CAG repeats did not reduce mutant HTT levels in an HD mouse model, although the ASOs ameliorated the phenotype independent of HTT levels. Overall, selective silencing of mutant proteins by CAG repeat-targeting oligonucleotides is yet to be investigated in vivo.
expression of AR24Q, REPU910 signi
type (24Q) and mutant (97Q)
REPU910 in NSC34 motor neuron-like cells stably expressing wild-
respectively (Figures S3A and S3B).
about 25%, 35%, and 45% at concentrations of 2.5, 5, and 25 nM,
5n M (Figures 1D and 1E). Correspondingly, REPU910 also suppressed
the expression of mutant AR by 40%
had a limited effect on wild-type AR protein expression but suppressed
different healthy controls (control Q30 and Q17). Notably, REPU910
from two different patients with SBMA (SBMA Q52 and Q48) and two
the highest knockdown ef
in vitro
use. REP showed
expression in the brainstem and spinal
expression in the olfactory bulb, thalamus, and cerebellum; and
low or hardly detectable expression in the brainstem and spinal
cord (Figure 3C). The expression levels of EGFP in the ipsilateral and contralateral cerebral hemispheres were nearly identical (Figure 3D).

Distribution of LUNAR-EGFP in the CNS
We also assessed the detailed distribution of LUNAR nanoparticles in additional experiments. At P4, coronal brain sections of mice that were i.c.v. injected with LUNAR-EGFP at P1 showed strong EGFP signals along the ventricle and in the frontal to temporal cortex as well as relatively weaker signals in other brain regions, such as the thalamus and cerebellum (Figure 3A). Immunohistochemistry for EGFP showed strong immunoreactivity, especially in the olfactory bulb and periventricular area (Figure 3B). Importantly, the finding of EGFP signals in the brain parenchyma confirms that i.c.v.-administered LUNAR nanoparticles penetrate the ependymal cells. Western blotting analysis of EGFP expression showed the following patterns: highest expression in the frontal and temporal cortex; moderate expression in the olfactory bulb, thalamus, and cerebellum; and low or hardly detectable expression in the brainstem and spinal cord (Figure 3C). The expression levels of EGFP in the ipsilateral and contralateral cerebral hemispheres were nearly identical (Figure 3D), indicating that i.c.v.-injected LUNAR nanoparticles were evenly distributed across hemispheres.

LUNAR-EGFP mRNA complexes are incorporated into neurons, astrocytes, and oligodendrocytes
We further investigated the type of cells that uptake LUNAR nanoparticles. Immunohistochemistry at P4 showed EGFP signals in the neurons and glial cells in the temporal cortex of LUNAR-EGFP-injected mice (Figure 4A). We also performed double immunofluorescence staining for EGFP and cell markers and found that EGFP signals were observed in the neurons, oligodendrocytes, and astrocytes (Figures 4B and 4C). These results suggest not only that LUNAR-EGFP was taken up by both the neurons and glial cells but also that the incorporated EGFP mRNA was efficiently translated by ribosomes.

Selective suppression of polyQ-expanded AR by i.c.v.-injected LUNAR-REP910 siRNA
Next, we investigated the efficacy of LUNAR-delivered REP910 siRNA (denoted LUNAR-REP910) in vivo. To assess its mutant allele selectivity, we used our transgenic mice carrying wild-type human AR with 24 CAGs (AR24Q mice) and mutant AR with 97 CAGs (AR97Q mice). We i.c.v. injected LUNAR-REP910 in the mice at P1 and assessed AR protein levels at P4 (Figure 5A). I.c.v. injection of maximum dose (1,800 ng) of REP910 had no adverse effect on mouse phenotypes, including motor function, growth, and survival.
Western blot analysis showed that LUNAR-REPU910 significantly suppressed mutant AR expression by ~90% in the temporal cortex and by ~70%, although not statistically significant, in the cerebellum, compared to vehicle (Figures 5B and 5C). In contrast, no apparent reduction was observed in the temporal cortex and cerebellum of AR24Q mice (Figures 5D and 5E), which demonstrates the allele-selective potency of LUNAR-REPU910 against expanded CAG repeats in vivo mouse brain tissue. Although the precise conversion of the bioavailability of REPU910 is difficult between diverse biological contexts, the pharmacological effects of 1,800 ng of REPU910 siRNA in the temporal cortex and the cerebellum are complementary to those of 5–25 nM and 2.5–5 nM in cell-culture experiments, respectively (Figures 1D, 1E, 5B, and 5C).

**LUNAR-REPU910 suppresses mutant huntingtin in the CNS of R6/2 HD mouse model**

To demonstrate the applicability of LUNAR-REPU910 to other polyQ diseases, we used a R6/2 HD mouse model harboring exon 1 huntingtin transgene with expanded CAG repeats (MUT-ex1 HTT). PCR analysis showed that the R6/2 mice used in this study had MUT-ex1 HTT containing approximately 160–190 expanded CAGs (Figure S5A). We i.c.v. injected LUNAR-REPU910 (1,800 ng) at P1 and analyzed the MUT-ex1 HTT protein levels at P4. Consistent with previous studies, western blot analysis revealed that an ~50 kDa band of MUT-ex1 HTT was detected by using 1C2 antibody against expanded polyQ proteins (Figure S5B); LUNAR-REPU910 was found to efficiently suppress MUT-ex1 HTT by ~70% in the temporal cortex of R6/2 mice (Figures S5C and S5D).

**LUNAR-REPU910 suppresses mutant AR in the skeletal muscle in AR97Q mice**

Finally, we investigated whether LUNAR-REPU910 suppresses mutant AR in the skeletal muscle of AR97Q mice, because peripheral AR suppression is also a candidate approach for the treatment of SBMA. We subcutaneously injected LUNAR-EGFP mRNA (1,800 ng) into the ipsilateral gastrocnemius muscle at P1 and assessed EGFP expression and distribution at P4. As a control, saline vehicle was simultaneously injected into the contralateral muscle (Figure 6A). Fluorescence imaging of the LUNAR-EGFP-injected hind limb showed high EGFP expression throughout the ipsilateral gastrocnemius muscle but no EGFP signal on the contralateral side (Figure 6B). Western blot analysis confirmed the EGFP expression in the EGFP-treated side of the muscle (Figure 6C). Immunohistochemistry of the muscle showed broad EGFP expression in the myocytes, demonstrating efficient cellular uptake and intracellular distribution of LUNAR nanoparticles (Figure 6D). Similarly, we subcutaneously injected LUNAR-REPU910 (1,800 ng) and saline vehicle to each hind limb at P1 in AR97Q mice and analyzed mutant AR expression levels at P4. Western blot analysis showed that LUNAR-REPU910 obtained a significant (~80%) suppression of mutant AR expression in the gastrocnemius muscle (Figures 6E and 6F).

**DISCUSSION**

Using both in vitro cell models and in vivo mouse models of SBMA, this study demonstrated the selectivity of UNA-modified CAG-siRNAs for expanded polyQ protein and their potential...
Consistent with previous reports,9,12 siRNA that was fully complementary to CAG repeats in human fibroblasts14, we found that REP910 siRNA suppressed AR mRNA levels, showing a similar tendency of its effect on AR protein levels. The difference between these studies may arise due to diverse effects of CAG-siRNAs on the mRNA of each gene.

We also demonstrated that LNP-delivered REP910 siRNA selectively suppressed mutant AR expression in the CNS of an SBMA mouse model while preserving the expression of wild-type AR with normal CAG repeats in transgenic mice. To our knowledge, this is the first report of the selective suppression of a polyQ protein by a double-stranded CAG-siRNA in vivo. Furthermore, we confirmed that the LNP-delivered REP910 siRNA also suppressed mutant polyQ-expanded protein in the muscle of the SBMA mouse model as well as in the CNS of HD mouse model. In this study, we used neonatal mice to test the efficacy of LNP-delivered CAG-siRNA, which enables us to assess the in vivo potency of CAG-siRNA in an efficient manner, but its therapeutic application to older mice will further provide valuable information for developing treatments for later-onset polyQ diseases.

LNP has attracted great attention as a delivery system for siRNA, and the first LNP-encapsulated siRNA (LNP-siRNA) was recently approved for clinical use in patients with transthyretin amyloidosis.32 LNP is accumulated in target cells by apolipoprotein E (APOE)-mediated endocytosis; thus, APOE plays a critical role in the intracellular delivery of siRNAs.33 Although the main target tissue of LNP-siRNAs is that of the liver, APOE-mediated uptake of LNP can also occur in the CNS.33 Several reports have shown that LNP-siRNA efficiently suppresses target gene expression in the rodent CNS,35–37 but the potency and detailed distribution of i.c.v.-administered LNP-siRNA had not been fully clarified. In the present study, the widespread distribution of LUNAR nanoparticles was observed across brain regions. Moreover, i.c.v.-injected LUNAR-REP910 selectively suppressed mutant AR expression in the brain in a glutamine repeat length-dependent manner. As siRNA concentration is not diluted by cell division in non-dividing cells,38 the effect of gene suppression can persist for several weeks once siRNA uptake by neurons has occurred.39 However, to reduce the frequency of siRNA administration, chemical modifications to increase half-life of oligonucleotides may be useful for clinical applications.

The potential efficacy of anti-androgen therapies against neurological symptoms has been demonstrated in both preclinical and clinical studies in SBMA.40 However, the benefit of such therapies is partially limited by accompanying sexual dysfunction and anti-anabolic actions on skeletal muscles; therefore, additional therapeutic strategies are needed. Previous studies have shown that the reduction of mutant AR by systemic or i.c.v.-administered gapmer ASOs ameliorates phenotypes of SBMA mouse models.28,41 Although these ASOs are promising therapeutic candidates, CAG repeat-targeting oligomers, such as REP910 siRNA, have an advantage in terms of their applicability as common treatments for polyQ diseases. Indeed, we demonstrated application in the treatment of polyQ diseases. UNA-modified CAG-siRNAs were shown to achieve selective knockdown of mutant allele expression of AR with CAG repeats in human fibroblasts.

In contrast to a previous study, which reported that UNA-modified CAG-siRNAs caused little alteration of HTT mRNA levels in HD patient fibroblasts,14 we found that REP910 siRNA suppressed AR mRNA levels, showing a similar tendency of its effect on AR protein levels. The difference between these studies may arise due to diverse effects of CAG-siRNAs on the mRNA of each gene.

Figure 4. LUNAR-EGFP mRNA complexes are incorporated into neurons, astrocytes, and oligodendrocytes
Vehicle or LUNAR-EGFP mRNA (1,800 ng) was i.c.v. injected into mice at P1. (A) Immunohistochemistry in the temporal cortex of mice at P4 shows EGFP expression in the neurons and glial cells. (B and C) Immunofluorescence staining shows EGFP expression in the neurons (B), astrocytes, and oligodendrocytes (C). Hoechst was used for nuclei staining, and NeuN, GFAP, and Olig2 were used as markers for neurons, astrocytes, and oligodendrocytes, respectively. Arrows indicate merged cells. Scale bars, 50 μm.
that LUNAR-REPU910 enabled efficient suppression of not only polyQ-expanded AR but also polyQ-expanded huntingtin protein in the CNS of mouse models.

A limitation of this study is that i.c.v.-administered LUNAR nanoparticles were barely distributed in the brainstem and spinal cord, so we were unable to assess the potency of REPU910 siRNA in lower motor neurons. In contrast, its potential applicability to the treatment of SBMA was demonstrated by the finding that LUNAR-REPU910 administered subcutaneously enabled suppression of mutant AR expression in the skeletal muscle, another therapeutic target for SBMA. However, further studies should explore the modification of nanoparticles and siRNAs to obtain the optimal distribution and duration of action to disease tissues for polyQ diseases. We are going to screen our lipid library for optimization of the LNP to enhance the tissue distribution of the siRNA. Otherwise, alternative administration routes, such as intrathecal injection, might improve the pharmacodynamic properties in the CNS.

In conclusion, we showed the selective suppression of mutant AR by UNA-modified CAG-siRNA in in vitro SBMA cell models and demonstrated that LNP-mediated delivery of the CAG-siRNA selectively reduces mutant AR levels in the in vivo brain of an SBMA mouse model. Furthermore, the LNP-delivered CAG-siRNA also suppressed mutant huntingtin in the CNS and mutant AR in the skeletal muscle in mice. These results provide a proof of concept of LNP-delivered CAG-siRNA for selective suppression of expanded polyQ protein in SBMA, as well as its broad applicability to other polyQ diseases.

**MATERIAL AND METHODS**

**Preparation of siRNA and mRNA**

All the siRNA sequences used in this study were synthesized by Integrated DNA Technologies (Corvalle, IA, USA). Co-transcriptionally capped EGFP mRNA was synthesized by T7 RNA polymerase using HiScribe T7 High Yield RNA Synthesis Kit from New England Biolabs (Ipswich, MA, USA) according to manufacturer’s instructions. Purity and concentration of the mRNA were measured by 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) and NanoDrop Spectrophotometer (ThermoFisher Scientific, Waltham, MA, USA), respectively.

**Preparation of LUNAR-mRNA and LUNAR-siRNA nanoparticles**

LUNAR nanoparticles encapsulating REPU910 siRNA or EGFP mRNA were prepared by mixing an ethanolic solution of lipids with an aqueous solution of RNA as previously described. Briefly, lipid excipients (ATX-Arcturus Therapeutics proprietary ionizable lipid, DSPC, cholesterol and PEG2000-DMG) are dissolved in ethanol at mole ratio of 58:7:33.5:1.5 (for siRNA) and 50:7:40:3 (for mRNA). An aqueous solution of the RNA is prepared in citrate buffer pH 3.5. The lipid mixture is then combined with the RNA solution at a flow rate ratio of 1:3 (v/v) using the NanoAssemblr microfluidic system (Precision NanoSystems). Nanoparticles thus formed are dialyzed against either Tris or HEPES buffer pH 7.4 using 100,000 MWCO dialysis tube (Repligen) at room temperature. Concentration of the formulation is adjusted to the final target RNA concentration using 100,000 MWCO Amicon Ultra centrifuge tubes (Millipore Sigma) followed by filtration through a 0.2 μm polyethersulfone sterilizing-grade filter. Post filtration, bulk formulation is aseptically filled into sterile Eppendorf tubes and...
frozen at $-70 \pm 10\,^\circ C$. Analytical characterization includes measurement of particle size and polydispersity using dynamic light scattering (ZEN3600, Malvern Instruments) and RNA content and encapsulation efficiency by a fluorometric assay using Ribogreen RNA reagent (Thermo Fisher Scientific).

**Construction of luciferase reporter vectors**

Open reading frames for human ATXN3 with either 24 or 74 CAG repeats were PCR-amplified using genomic DNA isolated from Machado-Joseph disease patient’s fibroblasts with ATXN3-specific primers containing either the Pml I or RsR G I site; they were then cloned in-frame downstream of firefly luciferase in the psiVer3 vector, which was constructed based on the psiCHECKTM2 vector (Promega, Madison, WI, USA), as shown in Figure S1. The resulting pArc vectors also contained a constitutively expressed Renilla luciferase gene, which served as an internal control to normalize transfection efficiency.

**Luciferase reporter assay**

The Dual-Luciferase Reporter Assay System (DLR assay system, Promega, Madison, WI, USA) was used to perform dual-reporter assays on psiCHECK2-based reporter systems. A total of 5,000 HEK293 cells (American Type Culture Collection) were plated onto a well of 96-well plate 1 day before the transfection. The cells were incubated at $37\,^\circ C$ in 100 $\mu L$ of DMEM (Life Technologies, Carlsbad, CA, USA) supplemented with 0.1 mM nonessential amino acids and 10% FBS (Life Technologies, Carlsbad, CA, USA). The reporter plasmid and siRNA were co-transfected with transfection reagent: Lipofectamine 3000 (Life Technologies, Carlsbad, CA, USA) was used to transfect the reporter plasmid (25 ng), and various amounts of siRNA together with P3000 were transfected into the cells according to the manufacturer’s protocol. One day after transfection, the cells were gently washed once with phosphate-buffered saline. Subsequently, 40 $\mu L$ per well of Passive Lysis Buffer (Promega, Madison, WI, USA) was added to the cells, which were then incubated with gentle rocking for 20 min at room temperature. Luciferase activities were measured using a Cytation 3 imaging reader (BioTek, Winooski, VT, USA), and the effects of the siRNA on reporter expression were calculated based on the ratio of firefly/Renilla, which was used to normalize cell number and transfection efficiency.

**Cell culture and transfection**

Dermal fibroblasts were collected at biopsy from genetically confirmed SBMA patients. Healthy control human fibroblasts were obtained from Kurabo Industries. The length of CAG repeats was determined by fragment analysis and Sanger sequencing of the PCR products. NSC34 motor neuron-like cells stably expressing AR24Q or AR97Q were established as previously described. Cells were maintained in DMEM supplemented with 10% FBS. Fibroblasts and NSC34 cells were plated in 6-well and 24-well plates 24 h before transfection, respectively. SiRNAs were transfected with
Lipofectamine RNAiMax transfection reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. Transfected cells were then cultured in DMEM with 10% FBS and 50 nM dihydrotosterone. RNA and protein were isolated 48 h after transfection.

**Animals**

Transgenic mice bearing chicken β-actin promoter-driven human AR with elongated or normal length of CAG repeat (AR97Q and AR24Q) were generated and maintained on a C57BL/6J background in the animal facility.23,44 The mice, genotyped using PCR of tail DNA, were allowed free access to water and a standard diet and maintained on a 12 h light/dark cycle.23 We mated AR97Q or AR24Q mice to wild-type C57BL/6J mice and randomly allocated newborn mice of them to each treatment group. Transgenic mice bearing human HTT promoter-driven human MUT-ex1 HTT (R6/2) were generated and maintained on a CBA × C57BL/6J background.19 We obtained R6/2 mice from the Jackson Laboratory, and their embryos were frozen and stored until use. We generated newborn mice by frozen embryo transfer into recipient Institute of Cancer Research mice and randomly allocated them to each treatment group. R6/2 mice were genotyped using PCR of tail DNA and the following primers for determining the presence of MUT-ex1 HTT transgene: forward/reverse 5’-CCGCTCAAGTCTGCTTTTTA-3’/5’-TGGAAGGACTT GAGGGACTC-3’. and the size of the CAG repeat lengths in the transgene: forward/reverse 5’-CCGCTCAAGTCTGCTTTTTA-3’/5’- GGCTGAGGAAGCTGAGGAG-3’. We used approximately 40 neonatal mice in total throughout this study. The number of mice used in each experiment is described in each figure legend.

**i.c.v. injection**

The procedure of i.c.v. injection was previously described.45 Briefly, P1 neonatal mice were cryoanesthetized on ice, and 2 μL of LUNAR-mRNA or LUNAR-siRNA in saline containing Fast Green FCF (0.01% [w/v]; Sigma-Aldrich, St. Louis, MO, USA) was injected into the left lateral ventricle using a 5 μL microsyringe (Hamilton Company, Reno, NV, USA) and a 33-gauge needle.

**Subcutaneous injection**

We subcutaneously injected LUNAR-mRNA or LUNAR-siRNA in saline containing Fast Green FCF (0.01% [w/v]; Sigma-Aldrich) around the gastrocnemius muscles of the left hind limb using a 5-μL microsyringe (Hamilton Company) and a 33-gauge needle. Vehicle was similarly injected in the same site of the right hind limb.

**Protein isolation and western blotting**

After mice were sacrificed, their brain regions and spinal cord were dissected and snap-frozen in powdered CO2 in acetone. Protein was isolated from mouse tissue and fibroblasts using Cellytic MT Cell Lysis Reagent (Sigma-Aldrich) supplemented with Halt Protease and Phosphatase Inhibitor Cocktails (Thermo Scientific, Waltham, MA, USA). We separated equal amounts of protein on 5%–20% SDS-PAGE gels (Wako, Osaka, Japan) and transferred them to Hybond-P membranes (GE Healthcare, Piscataway, NJ, USA). The following antibodies were used in this study: anti-AR (1:2,000; H280, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-GAPDH (1:5,000; 6C5, Abcam, Cambridge, MA, USA), anti-GFP (1:1,000; D5.1, Cell Signaling Technology, Beverly, MA, USA), and anti-polyQ 1C2 (1:2,000; MAB1574, Millipore, Billerica, MA, USA). The density of each band was quantified using ImageJ software (NIH, Bethesda, MD, USA).

**Immunohistochemistry and immunofluorescence**

After mouse brains were dissected, they were immediately fixed in a 10% buffered formalin solution. Sections (3 μm) were then deparaffinized, heated in a microwave for 15 min in a 10 mM citrate buffer (pH 6.0), and incubated overnight with the following primary antibodies: anti-GFP (1:200; D5.1, Cell Signaling Technology), anti-NeuN (1:100; MAB377, Millipore), anti-GFAP (1:1,000; ab53554, Abcam), and anti-Olig2 (1:250; MABN50, Millipore). For immunohistochemistry, the samples were incubated with a secondary antibody labeled with a polymer as part of the Envision+ system containing horseradish peroxidase (Dako Cytomation, Glostrup, Denmark). Photographs of immunohistochemically stained sections were captured using an optical microscope (BX51, Olympus). For immunofluorescence, the samples were incubated for 1 h with the following secondary antibodies: Alexa 488-conjugated goat anti-rabbit IgG (1:1,000; Invitrogen), Alexa-546-conjugated goat anti-mouse IgG (1:1,000; Invitrogen), and biotinylated horse anti-goat IgG (1:500; BA-9500, Vector Laboratories). Biotinylated secondary antibodies were visualized using Alexa-594-conjugated streptavidin (1:1,000; Invitrogen). Nuclei were stained with Hoechst 33342 (1:400; Invitrogen). Immunofluorescence-stained sections were mounted with ProLong Gold (Invitrogen) and then imaged with a fluorescent microscope (BX-710, Keyence, Osaka, Japan).

**RNA isolation and PCR**

Total RNA was extracted from the fibroblasts using TRIzol (Invitrogen) and RNeasy Mini Kit (QIAGEN, Hilden, Germany). The extracted RNA was then reverse-transcribed into first-strand cDNA using the ReverTra Ace qPCR RT Kit (Toyobo, Osaka, Japan). PCR amplification was performed using rTaq DNA polymerase (Toyobo) according to the manufacturer’s protocol. Quantitative PCR was performed using THUNDERBIRD SYBR qPCR Mix (Toyobo), and the amplified products were detected with the iCycler system (Bio-Rad Laboratories, Hercules, CA, USA). To analyze AR and GAPDH transcripts, the following PCR primers were used: AR forward/reverse, 5’-CGGAAGCTGAAACACTTG-G-3’/5’-ATGGCTTCCA GGACATTCCG-3’, GAPDH forward/reverse 5’-GAGTCAACGGA TTTGTCGT-3’/5’-TTGATTITTGGAGGAGTCTCG-3’.

**Statistical analysis**

We analyzed the data with an unpaired two-sided t test for comparisons of two groups and the one-way ANOVA with post hoc Dunnett’s test for multiple comparisons unless otherwise noted. Analyses were conducted in GraphPad Prism8 (GraphPad, San Diego, CA, USA).
Study approval
The collection of biopsied human fibroblasts and their use in this study was approved by the ethics committees of the Nagoya University Graduate School of Medicine (approval no. 2019-0406), the Keio University School of Medicine (approval no. 20080016), and the Aichi Medical University School of Medicine (approval no. 14-004). All animal experiments were performed in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals and with the approval of the Nagoya University Animal Experiment Committee (no. 20049).

SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.omtn.2021.02.007.

ACKNOWLEDGMENTS
This research was supported by AMED under grant number JP20lm0203005, the Japan Society for the Promotion of Science KAKENHI under grant numbers 17H04195 and 20H00527, and a KDA Research Grant. We thank the staffs of the Division of Experimental Animals, Nagoya University Graduate School of Medicine for their technical support.

AUTHOR CONTRIBUTIONS
Conceptualization, T.H., K.S., and M.K.; investigation and methodology, T.H., K.S., K.T., A.I.L., M.N., R.M., P.P.K., G.T., M.I., and K.O.; visualization, T.H., K.S., K.T., A.I.L., M.N., R.M., P.P.K., and M.K.; resources, K.T., A.I.L., M.N., R.M., P.P.K., P.C., Y.O., H.O., and M.K.; writing – original draft, T.H., K.S., K.T., A.I.L., M.N., R.M., P.P.K., P.C., Y.O., and M.K.; supervision, K.S. and M.K.; funding acquisition, K.S. and M.K.

DECLARATION OF INTERESTS
K.T., A.I.L., M.N., R.M., P.P.K., and P.C. are employees of Arcturus Therapeutics.

REFERENCES
1. Kennedy, W.R., Alter, M., and Sung, J.H. (1968). Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 18, 671–680.
2. La Spada, A.R., Wilson, E.M., Lubahn, D.B., Harding, A.E., and Fischbeck, K.H. (1991). Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352, 77–79.
3. Sahashi, K., and Katsuno, M. (2018). Pathogenesis of Polyglutamine Diseases. Published online October 15, 2018. 10.1002/9780470159020.a0021486.pub2.
4. Lieberman, A.P., Shakkottai, V.G., and Albin, R.L. (2019). Polyglutamine Repeats in Neurodegenerative Diseases. Annu. Rev. Pathol. 14, 1–27.
5. Wild, E.I., and Tabrizi, S.J. (2017). Therapies targeting DNA and RNA in Huntington’s disease. Lancet Neurol. 16, 837–847.
6. Gonzalez-Alegre, P. (2019). Recent advances in molecular therapies for neurodegenerative disease: triplet repeat disorders. Hum. Mol. Genet. 28 (R1), R80–R87.
7. Silva, A.C., Lobo, D.D., Martins, L.M., Lopes, S.M., Henriques, C., Duarte, S.P., Dobot, J.C., Nobre, R.J., and Pereira de Almeida, L. (2020). Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders. Brain 143, 407–429.
8. Fiszner, A., and Krzyzosiak, W.J. (2014). Oligonucleotide-based strategies to combat polyglutamine diseases. Nucleic Acids Res. 42, 6787–6810.
9. Hu, J., Matsui, M., Gagnon, K.T., Schwartz, J.C., Gabillet, S., Arar, K., Wu, J., Berprozvanny, I., and Corey, D.R. (2009). Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat. Biotechnol. 27, 478–484.
10. Gagnon, K.T., Pendergraff, H.M., Dealeavy, G.F., Swaye, E.E., Potier, P., Randolph, J., Roesch, E.B., Chattopadhyaya, J., Damha, M.J., Bennett, C.F., et al. (2010). Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry 49, 10166–10178.
11. Fiszner, A., Mykowska, A., and Krzyzosiak, W.J. (2011). Inhibition of mutant huntingtin expression by RNA duplex targeting expanded CAG repeats. Nucleic Acids Res. 39, 5578–5585.
12. Hu, J., Liu, J., and Corey, D.R. (2010). Allele-selective inhibition of huntingtin expression by switching to an mRNA-like RNAi mechanism. Chem. Biol. 17, 1183–1188.
13. Liu, J., Pendergraff, H., Narayannannar, K.J., Lackey, J.G., Kuchimanchi, S., Rajeev, K.G., Manoharan, M., Hu, J., and Corey, D.R. (2013). RNA duplexes with abasic substitutions are potent and allele-selective inhibitors of huntingtin and ataxin-3 expression. Nucleic Acids Res. 41, 8788–8801.
14. Ali, Y., Hu, J., Liu, J., Xiang, Q., Martinez, C., and Corey, D.R. (2013). Allele-selective inhibition of expression of huntingtin and ataxin-3 by RNA duplexes containing unlocked nucleic acid substitutions. Biochemistry 52, 9329–9338.
15. Hu, J., Liu, J., Narayannannar, K.J., Lackey, J.G., Kuchimanchi, S., Rajeev, K.G., Manoharan, M., Swaye, E.E., Lima, W.F., Prakash, T.P., et al. (2014). Allele-selective inhibition of mutant atrophin-1 expression by duplex and single-stranded RNAs. Biochemistry 53, 4510–4518.
16. Sun, X., Marque, L.O., Cordner, Z., Fruit, J.L., Bhat, M., Li, P.P., Kannan, G., Ladenheim, E.E., Moran, T.H., Margolis, R.L., and Rudnicki, D.D. (2014). Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity. Hum. Mol. Genet. 23, 6302–6317.
17. Datson, N.A., González-Barriga, A., Kourkouta, E., Wei, R., van de Giessen, J., Mulders, S., Kontkanen, O., Heikkinen, T., Lehtimäki, K., and van Deutkom, J.C.T. (2017). The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain. PloS ONE 12, e0171127.
18. Kourkouta, E., Wei, R., González-Barriga, A., Mulder, M., Verheul, R., Bosgra, S., Groenendaal, B., Puolivali, J., Toivanen, J., van Deutkom, J.C.T., and Datson, N.A. (2019). Suppression of Mutant Protein Expression in SCA3 and SCA1 Mice Using a CAG Repeat-Targeting Antisense Oligonucleotide. Mol. Ther. Nucleic Acids 17, 601–614.
19. Liu, C.R., and Cheng, T.H. (2015). Allele-selective suppression of mutant genes in polyglutamine diseases. J. Neurogenet. 29, 41–49.
20. Saudou, F., and Humbert, S. (2016). The Biology of Huntington. Neuron 89, 910–926.
21. Roé, L., Bañez-Coronel, M., Creus-Muncunill, J., Giralt, A., Alcalá-Vida, R., Mentxaka, G., Kagerbauer, B., Zornoza-Abellán, M.T., Aranda, Z., Venturi, V., et al. (2016). Targeting CAG repeat RNAs reduces Huntington’s disease phenotype independently of huntingtin levels. J. Clin. Invest. 126, 4319–4330.
22. Snead, N.M., Escamilla-Powers, J.R., Rossi, J.J., and McCaffrey, A.P. (2013). 5’ unlocked nucleic acid modification improves siRNA targeting. Mol. Ther. Nucleic Acids 2, e103.
23. Katsuno, M., Adachi, H., Kume, A., Li, M., Nakagomi, Y., Niwa, H., Sang, C., Kobayashi, Y., Doyu, M., and Sobue, G. (2002). Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neurology 35, 843–854.
24. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Herberington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S.W., and Bates, G.P. (1996). Exon 1 c silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nucleic Acids Res. 24, 854, e103.
25. Dragatsis, I., Goldowitz, D., Del Mar, N., Deng, Y.P., Meade, C.A., Liu, L., Sun, Z., Dietrich, P., Yue, J., and Reiner, A. (2009). CAG repeat lengths > or =35 attenuate the phenotype in the R6/2 Huntington’s disease transgenic mouse. Neurobiol. Dis. 33, 315–330.
26. Wang, C.E., Tytlacka, S., Orr, A.L., Yang, S.H., Graham, R.K., Hayden, M.R., Li, S., Chan, A.W.S., and Li, X.J. (2008). Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington’s disease. Mol. Mol. Genet. 17, 2738–2751.

27. Yang, H., Yang, S., Jing, L., Huang, L., Chen, L., Zhao, X., Yang, W., Pan, Y., Yin, P., Qin, Z.S., et al. (2020). Truncation of mutant huntingtin in knock-in mice demonstrates exon1 huntingtin is a key pathogenic form. Nat. Commun. 11, 2582.

28. Lieberman, A.P., Yu, Z., Murray, S., Peralta, R., Low, A., Guo, S., Yu, X.X., Cortes, C.J., Bennett, C.F., Monia, B.P., et al. (2014). Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy. Cell Rep. 7, 774–784.

29. Cortes, C.J., Ling, S.C., Guo, L.T., Hung, G., Tsunemi, T., Ly, L., Tokunaga, S., Lopez, E., Sopher, B.L., Bennett, C.F., et al. (2014). Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy. Neuron 82, 295–307.

30. Langkjaer, N., Pasternak, A., and Wengel, J. (2009). UNA (unlocked nucleic acid): a flexible RNA mimic that allows engineering of nucleic acid duplex stability. Bioorg. Med. Chem. 17, 5420–5425.

31. Hu, J., Liu, J., Yu, D., Chu, Y., and Corey, D.R. (2012). Mechanism of allele-selective inhibition of huntingtin expression by duplex RNAs that target CAG repeats: functional through the RNAi pathway. Nucleic Acids Res. 40, 11270–11280.

32. Ledford, H. (2018). Gene-silencing technology gets first drug approval after 20-year wait. Nature 560, 291–292.

33. Akinc, A., Querbes, W., De, S., Qin, J., Frank Kamenetsky, M., Jayaprakash, K.N., Jayaraman, M., Rajev, K.G., Cantley, W.L., Dorkin, J.R., et al. (2010). Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18, 1357–1364.

34. Cullis, P.R., and Hope, M.J. (2017). Lipid Nanoparticle Systems for Enabling Gene Therapies. Mol. Ther. 25, 1467–1475.

35. Rungtala, R.L., Choi, H.B., Lin, P.J.C., Ko, R.W.Y., Ashby, D., Nair, J., Manoharan, M., Cullis, P.R., and Macvica, R.A. (2013). Lipid nanoparticle delivery of sirna to silence neuronal gene expression in the brain. Mol. Ther. Nucleic Acids 2, e136.

36. Shyam, R., Ren, Y., Lee, J., Braunstein, K.E., Mao, H.Q., and Wong, P.C. (2015). Intraventricular delivery of siRNA nanoparticles to the central nervous system. Mol. Ther. Nucleic Acids 4, e242.

37. Helmschrodt, C., Höbel, S., Schöniger, S., Bauer, A., Bonicelli, J., Gringmuth, M., Fietz, S.A., Aigner, A., Richter, A., and Richter, F. (2017). Polyethyleneimine Nanoparticle-Mediated siRNA Delivery to Reduce α-Synuclein Expression in a Model of Parkinson’s Disease. Mol. Ther. Nucleic Acids 9, 57–68.

38. Bartlett, D.W., and Davis, M.E. (2006). Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 34, 322–333.

39. Omi, K., Tokunaga, K., and Hohjoh, H. (2004). Long-lasting RNAi activity in mammalian neurons. FEBS Lett. 558, 89–95.

40. Katsuno, M., Tanaka, F., Adachi, H., Banno, H., Suzuki, K., Watanabe, H., and Sobue, G. (2012). Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA). Prog. Neurobiol. 99, 246–256.

41. Sahashi, K., Katsuno, M., Hung, G., Adachi, H., Kondo, N., Nakatsuji, H., Tohnai, G., Iida, M., Bennett, C.F., and Sobue, G. (2015). Silencing neuronal mutant androgen receptor in a mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 24, 5985–5994.

42. Ramaswamy, S., Onnun, N., Tachikawa, K., Limphong, P., Vega, J.B., Karmali, P.P., Chivukula, P., and Verma, I.M. (2017). Systemic delivery of factor IX messenger RNA for protein replacement therapy. Proc. Natl. Acad. Sci. USA 114, E1941–E1950.

43. Onodera, K., Shimojo, D., Ishihara, Y., Yano, M., Miya, F., Banno, H., Kazumaki, N., Ito, T., Okada, R., de Araujo Herculano, B., et al. (2020). Unveiling synapse pathology in spinal bulbar muscular atrophy by genome-wide transcriptome analysis of purified motor neurons derived from disease specific iPSCs. Mol. Brain 13, 18.

44. Iida, M., Sahashi, K., Kondo, N., Nakatsuji, H., Tohnai, G., Tsutsumi, Y., Noda, S., Murakami, A., Onodera, K., Okada, Y., et al. (2019). Src inhibition attenuates polyglutamine-mediated neuromuscular degeneration in spinal and bulbar muscular atrophy. Nat. Commun. 10, 4262.

45. Sahashi, K., Hua, Y., Ling, K.K.Y., Hung, G., Rigo, F., Horev, G., Katsuno, M., Sobue, G., Ko, C.P., Bennett, C.F., and Krainer, A.R. (2012). TSUNAMI: an antisense method to phenocopy splicing associated diseases in animals. Genes Dev. 26, 1874–1884.